全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

重新审视类固醇类药物和阿司匹林在急性川崎病治疗中的作用
Review the Role of Corticosteroids and Aspirin in the Treatment of Acute Kawasaki Disease

DOI: 10.12677/ACM.2020.107209, PP. 1391-1396

Keywords: 川崎病，类固醇类药物，阿司匹林
Kawasaki Disease, Corticosteroids, Aspirin

Full-Text   Cite this paper   Add to My Lib

Abstract:

目前认为，口服大剂量阿司匹林(ASP) (80~100 mg/kg？d)与小剂量ASP (3~5 mg/kg？d)在改善川崎病(Kawasaki disease, KD)急性期冠状动脉预后方面，并没有明显的差异。类固醇类药物适用于冠状动脉损伤预后不良和使用静脉丙种球蛋白(IVIG)治疗的耐药KD患儿，无论是在高危患儿的早期治疗，还是静脉注射IVIG失败后的抢救治疗，类固醇类药物均是有效的，并且耐受性良好。
There is no significant difference between oral high-dose aspirin (ASP) (80 - 100 mg/kg？d) and low-dose ASP (3 - 5 mg/kg？d) in improving coronary prognosis in the acute phase of Kawasaki disease (KD). Corticosteroids are suitable for KD children with poor prognosis of coronary artery injury and intravenous gamma globulin (IVIG) resistance. Corticosteroids are effective and well tolerated in both early treatment of high-risk children and salvage treatment after failure of intravenous IVIG.

References

[1]  Chen, J.J., Ma, X.J., Liu, F., et al. (2016) Epidemiologic Features of Kawasaki Disease in Shanghai from 2008 through 2012. The Pediatric Infectious Disease Journal, 35, 7-12.
https://doi.org/10.1097/INF.0000000000000914
[2]  Singh, S., Vignesh, P. and Burgner, D. (2015) The Epidemiology of Kawasaki Disease: A Global Update. Archives of Disease in Childhood, 100, 1084-1088.
https://doi.org/10.1136/archdischild-2014-307536
[3]  Holman, R.C., Christensen, K.Y., Belay, E.D., et al. (2010) Racial/Ethnic Differences in the Incidence of Kawasaki Syndrome among Children in Hawaii. Hawaii Medical Journal, 69, 194-197.
[4]  McCrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment and Long-Term Management of Kawasaki Disease. A Scientific Statement for Health Professionals from the American Heart Association. Circulation Journal, 135, e927-e999.
[5]  Singh, S., Sharma, A. and Jiao, F.Y. (2016) Kawasaki Disease: Issues in Diagnosis and Treatment: A Developing Country Perspective. Indian Journal of Pediatrics, 83, 140-145.
https://doi.org/10.1007/s12098-015-1890-4
[6]  Michihata, N., Matsui, H., Fushimi, K., et al. (2015) Guideline-Concordant Treatment of Kawasaki Disease with Immunoglobulin and Aspirin and the Incidence of Coronary Artery Aneurysm. Clinical Pediatrics, 54, 1076-1080.
https://doi.org/10.1177/0009922814566932
[7]  Terai, M. and Shulman, S.T. (1997) Prevalence of Coronary Artery Abnormalities in Kawasaki Disease Is Highly Dependent on Gamma Globulin Dose But Independent of Salicylate Dose. Journal of Pediatrics, 131, 888-893.
https://doi.org/10.1016/S0022-3476(97)70038-6
[8]  Dhanrajani, A. and Yeung, R.S.M. (2017) Revisiting the Role of Steroids and Aspirin in the Management of Acute Kawasaki Disease. Current Opinion in Rheumatology, 29, 547？552.
https://doi.org/10.1097/BOR.0000000000000425
[9]  Gurbel, P.A., Bliden, K.P., DiChiara, J., et al. (2007) Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results from the Aspirin-Induced Platelet Effect (ASPECT) Study. Circulation, 115, 3156-3164.
https://doi.org/10.1161/CIRCULATIONAHA.106.675587
[10]  Dallaire, F., Fortier-Morissette, Z., Blais, S., et al. (2017) Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease. Pediatrics, 139, e20170098.
https://doi.org/10.1542/peds.2017-0098
[11]  Durongpisitkul, K., Gururaj, V.J., Park, J.M., et al. (1995) The Prevention of Coronary Artery Aneurysm in Kawasaki Disease: A Meta-Analysis on the Efficacy of Aspirin and Immunoglobulin Treatment. Pediatrics, 96, 1057-1061.
[12]  Furusho, K., Kamiya, T., Nakano, H., et al. (1992) Intravenous γ-Globulin for Kawasaki Disease. Acta Paediatrica Japonica, Overseas Edition, 33, 799-804.
https://doi.org/10.1111/j.1442-200X.1991.tb02611.x
[13]  Kato, H., Koike, S. and Yokoyama, T. (1979) Kawasaki Disease: Effect of Treatment on Coronary Artery Involvement. Pediatrics, 63, 175-179.
[14]  JCS Joint Working Group (2010) Guidelines for Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease (JCS 2008)-Digest Version. Circulation Journal, 74, 1989-2020.
https://doi.org/10.1253/circj.CJ-10-74-0903
[15]  张胜, 梁雪. 川崎病治疗研究进展[J]. 国际儿科学杂志, 2018, 45(8): 584-588.
[16]  Eleftheriou, D., Levin, A.M., Shingadia, D., et al. (1988) Management of Kawasaki Disease. The Journal of Pediatrics, 113, 1116-1117.
https://doi.org/10.1016/S0022-3476(88)80596-1
[17]  Sundel, R.P., Burns, J.C., Baker, A., et al. (1993) Gamma Globulin Re-Treatment in Kawasaki Disease. Journal of Pediatrics, 123, 657-659.
https://doi.org/10.1016/S0022-3476(05)80972-2
[18]  Simic, M. (1999) Corticosteroids in the Treatment of the Acute Phase of Kawasaki Disease. Journal of Pediatrics, 135, 465-469.
https://doi.org/10.1016/S0022-3476(99)70169-1
[19]  Sundel, R.P., Baker, A.L., Fulton, D.R., et al. (2003) Corticosteroids in the Initial Treatment of Kawasaki Disease: Report of a Randomized Trial. The Journal of Pediatrics, 142, 611-616.
https://doi.org/10.1067/mpd.2003.191
[20]  Inoue, Y., Okada, Y., Shinohara, M., et al. (2006) A Multicenter Prospective Randomized Trial of Corticosteroids in Primary Therapy for Kawasaki Disease: Clinical Course and Coronary Artery Outcome. Journal of Pediatrics, 149, 336-341.
https://doi.org/10.1016/j.jpeds.2006.05.025
[21]  Kobayashi, T., Saji, T., Otani, T., et al. (2012) Efficacy of Immunoglobulin plus Prednisolone for Prevention of Coronary Artery Abnormalities in Severe Kawasaki Disease (RAISE Study): A Randomized, Open-Label, Blinded-End- points Trial. The Lancet, 379, 1613-1620.
https://doi.org/10.1016/S0140-6736(11)61930-2
[22]  Chen, S., Dong, Y. and Marcio, G.K. (2016) Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention: A Systematic Review and Meta-Analysis. JAMA Pediatrics, 170, 1156-1163.
https://doi.org/10.1001/jamapediatrics.2016.2055
[23]  Wardle, A.J., Kiddy, H.C., Seager, M.J., et al. (2014) Corticosteroids for the Treatment of Kawasaki Disease in Children. Cochrane Database of Systematic Reviews, No. 8, CD011188.
https://doi.org/10.1002/14651858.CD011188
[24]  Chen, S., Dong, Y., Yin, Y., et al. (2013) Intravenous Immunoglobulin plus Corticosteroid to Prevent Coronary Artery Abnormalities in Kawasaki Disease: A Meta-Analysis. Heart, 99, 76-82.
https://doi.org/10.1136/heartjnl-2012-302126

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133